Physician profile
Yong Lin
NPI 1780772947
$12,181.72
in general payments reported to CMS, 2019-2025
20 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,298 · 2020: $798 · 2021: $1,595 · 2022: $1,340 · 2023: $1,493 · 2024: $1,572 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,151.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,502.72 | 2019-2025 | Vemlidy, Livdelzi |
| Amgen INC. | $2,714.77 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,691.93 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,210.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $871.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Optinose US, INC. | $284.12 | 2019-2021 | |
| Amarin Pharma, INC. | $278.63 | 2019-2020 | |
| Lilly USA, LLC | $251.71 | 2019-2023 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $239.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.07 | 2019-2025 | |
| Madrigal Pharmaceuticals | $136.90 | 2025 | Rezdiffra |
| Idorsia Pharmaceuticals US INC | $116.94 | 2023 | Quviviq |
| Foundation Medicine, INC. | $116.67 | 2023 | |
| Axsome Therapeutics, INC. | $103.32 | 2025 | Symbravo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $97.85 | 2024 | |
| Lundbeck LLC | $96.97 | 2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $23.33 | 2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $22.05 | 2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $13.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.